MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) has announced the European launch of its OviTex Inguinal Reinforced Tissue Matrix, the first reinforced tissue matrix explicitly designed for laparoscopic and robotic-assisted inguinal hernia repairs. The product’s debut overseas follows a successful rollout in the U.S. last year, where it generated more than $1 million in sales during its first year and saw increasing adoption among surgeons.
A Breakthrough in Hernia Repair Innovation
OviTex Inguinal Reinforced Tissue Matrix represents a new approach to inguinal hernia repair, providing an innovative, naturally derived alternative to traditional synthetic mesh. The product is available in Europe in two trocar-compatible configurations, offering either three or four anatomically shaped layers. These design variations allow surgeons to customize repairs to meet specific patient needs and optimize procedural techniques.
This latest addition to TELA Bio’s portfolio builds on the OviTex platform, which has already established itself globally in hernia repair. Utilizing ovine rumen interwoven with a minimum amount of polymer for strength, OviTex products are engineered to reduce the permanent polymer footprint while supporting natural tissue healing.
Over 69,000 OviTex implants have been performed globally since its introduction, supported by more than 40 published studies and presentations highlighting its clinical success. “This robust clinical experience demonstrates the potential of biologically reinforced devices like OviTex to transform outcomes in hernia repair,” TELA Bio emphasized in a statement.
Evidence of Success
The effectiveness of the OviTex platform has been showcased in studies such as the ReBAR technique trial led by Dr. Paul Szotek, Medical Director of the Indiana Hernia Center. This study evaluated robotic-assisted inguinal TAPP (Transabdominal Preperitoneal Patch) repairs using OviTex Core Permanent, observing a low recurrence rate of just 1.2% over an average 1.5-year follow-up period among 259 patients.
Aiming to Lead in the European Market
TELA Bio’s entrance into Europe represents a significant opportunity to meet the growing demand for advanced solutions in robotic-assisted procedures across the region.
“As the adoption of robotic-assisted procedures continues to expand across Europe, there is great opportunity for naturally derived devices that support healing and have strong clinical data,” said Bill Allan, President of TELA Bio’s Europe Operations. “OviTex Inguinal is purpose-built to address that need. In the European market—where shared decision-making between surgeons and patients is a hallmark of surgical planning, this product is an ideal fit. We believe it offers European surgeons a compelling option that is designed to deliver on both clinical performance and patient expectations.”
Looking Ahead
With its innovative design, proven track record, and market-ready configurations, OviTex Inguinal Reinforced Tissue Matrix is poised to make a significant impact on hernia repair in Europe. This launch not only demonstrates TELA Bio’s commitment to advancing surgical techniques but also its focus on offering solutions aligned with patient and surgeon needs.
This milestone reflects both the success of OviTex in the U.S. and the company’s strong focus on international expansion, paving the way for growth in one of the most advanced surgical markets in the world.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.